Basketter D A
St John's Institute of Dermatology, St Thomas' Hospital, London, UK.
Br J Dermatol. 2008 Aug;159(2):267-73. doi: 10.1111/j.1365-2133.2008.08625.x. Epub 2008 May 22.
Allergic contact dermatitis (ACD) is to a considerable extent a preventable disease. Limitation can be achieved by correct identification of skin sensitizers, characterization of their potency, understanding human skin exposure and application of good risk assessment/management strategies. Various methods exist which are accurate for the predictive identification of chemicals that possess skin-sensitizing properties. These are enshrined in regulations that aim to provide a harmonized approach to hazard identification. One of the methods, the local lymph node assay, also delivers information on the relative potency of sensitizers. Efforts are continuing in the European Union and at the Organization for Economic Cooperation and Development to use elements of this information for regulatory categorization of skin sensitizers. However, greater use can be made of this potency information in the application of quantitative risk assessments. Such assessments depend also on the availability of accurate data on human skin exposure, one aspect where legislation has little role to play. Management of risks by restriction of skin exposure is, in contrast, a key point where legislation can play an important role, helping to establish a level playing field for industry and setting good standards based on the legislator's ability to access all data. Ultimately, the combination of accurate hazard identification, potency measurement, risk assessment and management, underpinned by enabling legislation, will lead to reduction of ACD. For individuals who do still develop contact allergy, avoidance of ACD should continue to be a goal, based on raising awareness of skin protection, allergen labelling and other skincare strategies.
过敏性接触性皮炎(ACD)在很大程度上是一种可预防的疾病。通过正确识别皮肤致敏剂、确定其效力特征、了解人体皮肤接触情况以及应用良好的风险评估/管理策略,可以实现对该病的控制。现有多种方法可准确预测具有皮肤致敏特性的化学物质。这些方法已纳入法规,旨在提供统一的危害识别方法。其中一种方法,即局部淋巴结试验,还能提供有关致敏剂相对效力的信息。欧盟和经济合作与发展组织正在继续努力,利用这些信息的要素对皮肤致敏剂进行监管分类。然而,在应用定量风险评估时,可以更多地利用这种效力信息。此类评估还取决于是否有准确的人体皮肤接触数据,而在这方面立法几乎无法发挥作用。相比之下,通过限制皮肤接触来管理风险是立法可以发挥重要作用的关键领域,有助于为行业建立公平的竞争环境,并根据立法者获取所有数据的能力制定良好标准。最终,在支持性立法的基础上,将准确的危害识别、效力测量、风险评估和管理相结合,将减少过敏性接触性皮炎的发生。对于仍会发生接触性过敏的个体,基于提高皮肤保护意识、过敏原标签和其他护肤策略,避免过敏性接触性皮炎仍应是一个目标。